Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

This study compared the plasma amprenavir pharmacokinetics of the human immunodeficiency virus (HIV) protease inhibitors amprenavir (Agenerase) 1,200 mg twice daily (BID) and the amprenavir prodrug GW433908, a formulation that substantially reduces the number of tablets per dose compared with ampren...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wood, Robin, Arasteh, Keikawus, Stellbrink, Hans-Jürgen, Teofilo, Eugenio, Raffi, François, Pollard, Richard B., Eron, Joseph, Yeo, Jane, Millard, Judith, Wire, Mary Beth, Naderer, Odin J.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2004
Matèries:
Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC310156/
https://ncbi.nlm.nih.gov/pubmed/14693528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.1.116-123.2004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars